Holen Sie sich die Stockscreener-App
30.99
0.61%
-0.19
Handel nachbörslich:
30.99
Schlusskurs vom Vortag:
$31.18
Offen:
$31.3
24-Stunden-Volumen:
621.05K
Relative Volume:
1.01
Marktkapitalisierung:
$1.49B
Einnahmen:
$447.57M
Nettoeinkommen (Verlust:
$-38.92M
KGV:
-37.34
EPS:
-0.83
Netto-Cashflow:
$-1.15M
1W Leistung:
+3.23%
1M Leistung:
-6.37%
6M Leistung:
-17.25%
1J Leistung:
+40.86%
1-Tages-Spanne:
$30.41
$31.59
1-Wochen-Bereich:
$28.52
$31.82
52-Wochen-Spanne:
$18.94
$43.11
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Vergleichen Sie ATRC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
30.99 | 1.49B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
536.51 | 189.75B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
95.75 | 48.62B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
167.22 | 48.37B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
245.04 | 35.18B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.27 | 16.46B | 3.90B | 392.30M | 288.10M | 1.95 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
When (ATRC) Moves Investors should Listen - news.stocktradersdaily.com
AtriCure Q1 2025 presentation: Revenue up 13.6%, raises full-year guidance - Investing.com
Dimensional Fund Advisors LP Purchases 136,015 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure CEO details growth trajectory toward becoming a $1B company - The Business Journals
AtriCure targets $517M-$527M revenue in 2025 with strong growth in appendage management and pain management - MSN
Left Atrial Appendage Closure Market to Set Phenomenal Growth - openPR.com
AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Call Transcript - Insider Monkey
Shareholders in AtriCure (NASDAQ:ATRC) have lost 40%, as stock drops 11% this past week - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch - simplywall.st
Needham cuts AtriCure stock target to $44, maintains buy rating By Investing.com - Investing.com Nigeria
AtriCure price target lowered to $52 from $58 at BTIG - TipRanks
AtriCure price target lowered to $51 from $52 at Canaccord - TipRanks
AtriCure’s Strong Q1: Revenue Growth and Challenges - TipRanks
Needham cuts AtriCure stock target to $44, maintains buy rating - Investing.com Australia
UBS Adjusts AtriCure (ATRC) Price Target Amid Core Business Stre - GuruFocus
AtriCure, Inc. SEC 10-Q Report - TradingView
UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating - marketscreener.com
14 Analysts Assess AtriCure: What You Need To Know - Benzinga
AtriCure (ATRC) Target Price Revised Amid Mixed Sector Performan - GuruFocus
Q1 2025 AtriCure Inc Earnings Call - Yahoo Finance
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
AtriCure (ATRC) Buy Rating Reaffirmed Despite Adjusted Price Tar - GuruFocus
JMP maintains AtriCure stock $60 target post 1Q25 results - Investing.com
JMP maintains AtriCure stock $60 target post 1Q25 results By Investing.com - Investing.com India
AtriCure Inc (ATRC) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
(ATRC) Investment Report - news.stocktradersdaily.com
AtriCure, Inc. Reports Strong Q1 2025 Growth - TipRanks
AtriCure Inc (ATRC) Q1 2025 Earnings: EPS of -$0.14 Beats Estima - GuruFocus
Earnings call transcript: AtriCure Q1 2025 beats EPS expectations, stock up 2.9% - Investing.com Nigeria
AtriCure: Q1 Earnings Snapshot - Midland Daily News
ATRC Revenue Forecast for 2025 and Earnings Outlook | ATRC Stock News - GuruFocus
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
AtriCure Reports First Quarter 2025 Financial Results - BioSpace
AtriCure (ATRC) Exceeds Q1 Revenue Expectations with Strong Prod - GuruFocus
ATRICURE Earnings Results: $ATRC Reports Quarterly Earnings - Nasdaq
Earnings Flash (ATRC) ATRICURE INC. Posts Q1 Revenue $123.6M, vs. FactSet Est of $122.9M - marketscreener.com
Medical Device Giant AtriCure Posts Double-Digit Growth: Q1 Revenue Hits $124M as Margins Expand - Stock Titan
AtriCure Earnings Preview - Benzinga
Press Release Distribution & PR Platform - ACCESS Newswire
Left Appendage Occlusion Device Market Top Companies Study - openPR.com
Cryoablation Market Set to Witness Significant Growth by 2032 | - openPR.com
AtriCure Announces First Use of the AtriClip PRO-Mini® Device | ATRC Stock News - GuruFocus
AtriCure Announces First Use of the AtriClip PRO-Mini® Device | - GuruFocus
AtriCure launches smaller device for heart surgery By Investing.com - Investing.com South Africa
AtriCure announces first use of newest AtriClip device - MassDevice
AtriCure Reports 1st Use of Newest AtriClip LAA Exclusion System - Medical Product Outsourcing
AtriCure launches smaller device for heart surgery - Investing.com Australia
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.40%
0.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):